- Recipharm and ProductLife Group have announced a strategic partnership to support biopharma companies from early-stage development to market access.
- The collaboration integrates Recipharm’s CDMO capabilities with PLG’s regulatory and market expertise to reduce compliance and supply chain challenges.
Recipharm, a global contract development and manufacturing organisation (CDMO), has entered into a strategic collaboration with ProductLife Group (PLG), a provider of regulatory and product development services, to streamline the path to market for (bio)pharmaceutical companies.
The agreement aims to accelerate clinical development timelines by integrating Recipharm’s manufacturing capabilities with PLG’s regulatory and market access expertise. This approach is designed to help companies manage complex global requirements while reducing development risks and delays.
The partnership grants Recipharm’s clients direct access to PLG’s global network of regulatory professionals and services. Simultaneously, PLG’s customers gain entry to Recipharm’s development and manufacturing infrastructure, including predictive biologics modelling and intelligent manufacturing support.
“This partnership brings together Recipharm’s development and manufacturing expertise, with PLG’s 2,000 regulatory experts, operating across 150 countries,” said Greg Behar, CEO of Recipharm.
By aligning regulatory strategy with operational planning early in the product lifecycle, the two companies aim to deliver a unified solution for biopharma firms seeking to improve compliance and reduce time to market.
Stay ahead of trends and best practices
